We set out to validate the expression of the three cfRNA biomarkers – HPGD, PACS1, and TDP2 identified in our in-house cfRNA and CRC tissue samples using an independent cohort of pre- and post-surgical cfRNA samples (N=36) and published TCGA CRC tumor and tumor-adjacent samples (N=453). This evidence concerns the gene TDP2 and neoplasm.